WASHINGTON, D.C. and NORWELL, Mass. — Three prominent leaders from key federal health agencies are slated to headline the upcoming 2026 NORD® Rare Diseases and Orphan Products Breakthrough Summit®, establishing a powerful bridge between government policy, biomedical science, and the millions of Americans impacted by uncommon medical conditions.
Acting Commissioner of Food and Drugs Kyle Diamantas, J.D., National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., and Stephanie E. Haridopolos, M.D., DABFM, Director of National Health Communications for the Office of the Surgeon General and Principal Deputy Assistant Secretary for Health Policy, will address an audience of more than 900 rare disease leaders. The participants—representing patient advocacy groups, industry innovators, policymakers, researchers, and clinicians—will gather from October 25 through 27 in Washington, D.C., for the nation’s largest and longest-standing rare disease event.
Now entering its 16th year, the annual Breakthrough Summit serves as a critical forum for tackling the most complex challenges and exploring new opportunities to scale solutions for the more than 30 million children and adults living with rare diseases in the United States.
Pam Gavin, Chief Executive Officer of the National Organization for Rare Disorders (NORD), emphasized the critical timing of the high-level federal participation. “Rare disease is at a pivotal moment, and it is important for our community to hear directly from the federal leaders helping shape what comes next,” Gavin said. She noted that their presence reflects a longstanding and robust partnership among NORD, the FDA, the NIH, and the Office of the Surgeon General, underscoring a shared commitment to the rare disease population.
“The work they lead across research, regulation and public health is critical to building on today’s scientific breakthroughs and translating that progress into meaningful advances for people living with rare diseases,” Gavin added.
The event comes at a time of profound transformation and mounting expectation for the 1 in 10 Americans who face a rare disease diagnosis. Rapidly evolving scientific discoveries are creating unprecedented possibilities for earlier detection and intervention. At the same time, cutting-edge technologies and novel therapeutic development paradigms are placing heavy demands on the nation’s research infrastructure, regulatory frameworks, and healthcare systems to keep pace. The active involvement of federal leadership highlights the indispensable need for cross-sector collaboration—uniting government agencies, academic research centers, clinical medicine, private industry, and patient communities—to accelerate the delivery of safe, effective treatments.
FDA Leadership and Regulatory Priorities
As Acting Commissioner of Food and Drugs, Kyle Diamantas leads the federal agency tasked with evaluating and regulating the drugs, biologics, medical devices, and diagnostics that serve as lifelines for patients with rare conditions. Demonstrating an early focus on engagement, Diamantas organized a dedicated roundtable with rare disease advocates, including representatives from NORD, immediately upon stepping into his leadership role. The session allowed agency leadership to listen directly to community stakeholders regarding the systemic hurdles and unique regulatory challenges faced by rare disease developers and patients.
At the Breakthrough Summit, Diamantas’s address will offer attendees a direct window into the FDA’s strategic regulatory priorities and evolving pathways. These regulatory mechanisms are instrumental in shaping the future of therapeutic innovation, particularly as advanced therapies such as gene-targeting treatments and complex biologics push the boundaries of traditional regulatory science.
Complementing the Acting Commissioner’s keynote address, the Summit will feature a comprehensive federal regulatory panel. This session will bring together senior leadership from across the FDA, including representatives from the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the agency’s dedicated Rare Disease Innovation Hub. Together, these regulatory experts will provide multi-faceted perspectives spanning traditional small-molecule drugs, cutting-edge cellular and gene therapies, and modern medical devices and diagnostics.
NIH and the Frontiers of Biomedical Research
At the helm of the National Institutes of Health, Dr. Jay Bhattacharya oversees the world’s preeminent biomedical research enterprise. The NIH plays a foundational role in fueling the fundamental scientific discoveries that underpin the development of next-generation diagnostics, life-changing treatments, and eventual cures for rare conditions.

Dr. Bhattacharya’s keynote will center on the cutting-edge science driving today’s rare disease breakthroughs. This includes the expanding integration of artificial intelligence and machine learning into electronic health record data to uncover hidden patterns and accelerate diagnoses. Furthermore, the NIH is heavily engaged in high-impact public-private partnerships aimed at establishing standardized platforms and shared workflows. These initiatives are designed to streamline the development and delivery of gene-targeted therapies, ultimately reducing the time it takes to move promising science from academic laboratories to patients in need.
Dr. Bhattacharya’s insights are viewed as essential for understanding how the various institutes and centers within the NIH coordinate their efforts. By fostering a cohesive, cross-disciplinary approach, the agency strives to support both pediatric and adult patients who navigate the complexities of living with one or more rare diseases.
Advancing Public Health and Newborn Screening
Bringing a deep, personal commitment to rare disease advocacy into her public service, Dr. Stephanie E. Haridopolos plays a multi-faceted leadership role within the Office of the Surgeon General and the Office of the Assistant Secretary for Health. During the Breakthrough Summit, Dr. Haridopolos will address attendees regarding critical public health initiatives, with a primary focus on the expansion and modernization of newborn screening programs.
In recognition of her sustained impact on public policy, Dr. Haridopolos will be honored during the event with NORD’s 2026 Rare Impact Award® in the category of Policy Changemaker. Her recognition stems from monumental policy milestones achieved in 2025, when two devastating rare conditions—Duchenne muscular dystrophy and metachromatic leukodystrophy—were officially added to the Recommended Uniform Screening Panel (RUSP). Dr. Haridopolos played a key leadership role in advancing these crucial additions.
Beyond her work on the RUSP, Dr. Haridopolos has been a vital contributor to the Newborn Screening Working Group. This collaborative body is tasked with systematizing and modernizing the operational framework of the RUSP, paving the way for broader screening panels and vastly expanded opportunities for early diagnosis and timely clinical intervention for newborns affected by rare disorders.
A Community United for Progress
The convergence of top federal health officials, regulatory experts, industry pioneers, and patient advocates at the 2026 Breakthrough Summit underscores a shared national priority. For the millions of individuals and families navigating the isolating and often exhausting journey of a rare disease, the event represents a focal point of hope and strategic momentum.
Registration and a complete, up-to-date agenda for the 16th annual NORD Breakthrough Summit are available online through the official event portal at NORDSummit.org.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) is an independent, nonpartisan 501(c)(3) nonprofit organization dedicated to identifying, treating, and curing rare disorders through educational programs, advocacy, research, and patient and community services. NORD represents more than 350 disease-specific member patient organizations and maintains a collaborative Rare Disease Centers of Excellence network spanning over 170 premier medical and research institutions and children’s hospitals nationwide. Through its multifaceted initiatives, NORD continues to drive systemic advancements in care, research, and public policy on behalf of the greater rare disease community. Additional information can be found online at rarediseases.org.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders
[email protected]
719-330-4053
